Research Analysts Set Expectations for BPMC Q1 Earnings

Blueprint Medicines Co. (NASDAQ:BPMC) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Blueprint Medicines in a research report issued to clients and investors on Thursday, October 31st. HC Wainwright analyst A. Fein anticipates that the biotechnology company will post earnings of ($0.60) per share for the quarter. HC Wainwright has a “Buy” rating and a $135.00 price objective on the stock. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.77) per share. HC Wainwright also issued estimates for Blueprint Medicines’ Q2 2025 earnings at ($0.41) EPS and Q3 2025 earnings at ($0.19) EPS.

Other equities analysts have also recently issued research reports about the stock. Morgan Stanley lifted their target price on shares of Blueprint Medicines from $110.00 to $115.00 and gave the stock an “equal weight” rating in a research report on Friday, July 12th. Robert W. Baird lifted their price target on Blueprint Medicines from $112.00 to $127.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Guggenheim upped their price objective on Blueprint Medicines from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Baird R W upgraded Blueprint Medicines to a “strong-buy” rating in a research note on Friday, August 2nd. Finally, Wells Fargo & Company reduced their price target on shares of Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $120.39.

Blueprint Medicines Stock Performance

Shares of BPMC stock opened at $91.88 on Monday. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.65. The firm has a 50-day moving average of $88.79 and a 200-day moving average of $98.55. Blueprint Medicines has a one year low of $56.74 and a one year high of $121.90. The company has a market cap of $5.84 billion, a P/E ratio of -43.54 and a beta of 0.59.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.08. The business had revenue of $128.20 million during the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. Blueprint Medicines’s quarterly revenue was up 126.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($2.20) EPS.

Institutional Trading of Blueprint Medicines

Institutional investors and hedge funds have recently bought and sold shares of the company. Triad Wealth Partners LLC bought a new stake in shares of Blueprint Medicines during the 2nd quarter valued at about $27,000. Covestor Ltd increased its holdings in shares of Blueprint Medicines by 9,700.0% in the 1st quarter. Covestor Ltd now owns 294 shares of the biotechnology company’s stock worth $28,000 after buying an additional 291 shares during the last quarter. Headlands Technologies LLC raised its position in shares of Blueprint Medicines by 105.2% during the 1st quarter. Headlands Technologies LLC now owns 667 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 342 shares in the last quarter. Natixis purchased a new stake in shares of Blueprint Medicines during the 1st quarter valued at $73,000. Finally, CWM LLC grew its position in Blueprint Medicines by 114.6% in the second quarter. CWM LLC now owns 1,105 shares of the biotechnology company’s stock worth $119,000 after acquiring an additional 590 shares in the last quarter.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, insider Fouad Namouni sold 3,633 shares of the firm’s stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total value of $324,499.56. Following the completion of the transaction, the insider now owns 69,070 shares in the company, valued at $6,169,332.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.21% of the company’s stock.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.